Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Long-Term Investments (2011 - 2026)

Standard Biotools (LAB) reported Long-Term Investments of $71.4 million for Q1 2026, up 177.64% on a QoQ basis from $25.7 million in Q4 2025.

Standard Biotools (LAB) has 7 years of Long-Term Investments data on file, last reported at $71.4 million in Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $71.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.4 million (changed N/A YoY) and the FY2025 annual result came in at $25.7 million, changed N/A from the prior year.
Long-Term Investments advanced to $71.4 million in Q1 2026 per LAB's latest filing, from $25.7 million in the prior quarter.
Across five years, Long-Term Investments topped out at $71.4 million in Q1 2026 and bottomed at $19.5 million in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	152.82 Bn	146.17 Bn	6.27 Bn	1.09 Bn
2	Stryker	115.07 Bn	112.19 Bn	3.81 Bn	-
3	Medtronic	95.25 Bn	87.08 Bn	5.76 Bn	-
4	Boston Scientific	71.38 Bn	70.17 Bn	3.61 Bn	-
5	Edwards Lifesciences	51.08 Bn	47.41 Bn	1.29 Bn	285.60 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	166.25 Mn
7	Dexcom	28.84 Bn	27.72 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.56 Bn	26.49 Bn	1.98 Bn	-
9	Steris	20.71 Bn	20.30 Bn	697.10 Mn	-
10	Standard Biotools	448.37 Mn	-6.80 Mn	11.31 Mn	71.36 Mn

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2026	71.36 Mn
Dec 31, 2025	25.70 Mn
Sep 30, 2025	19.49 Mn
Dec 31, 2015	6.49 Mn
Sep 30, 2015	17.03 Mn
Jun 30, 2015	27.12 Mn
Mar 31, 2015	18.51 Mn
Dec 31, 2014	27.50 Mn
Sep 30, 2014	51.96 Mn
Jun 30, 2014	62.29 Mn
Mar 31, 2014	15.13 Mn
Dec 31, 2013	1.94 Mn
Sep 30, 2013	19.14 Mn
Jun 30, 2013	23.07 Mn
Mar 31, 2013	7.30 Mn
Dec 31, 2012	3.67 Mn
Sep 30, 2012	3.20 Mn
Jun 30, 2012	1.00 Mn
Mar 31, 2012	6.07 Mn
Dec 31, 2011	1.50 Mn
Sep 30, 2011	1.34 Mn
Jun 30, 2011	1.34 Mn